DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation

Information source: University of Sao Paulo General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Renal Osteodystrophy

Intervention: Zoledronic acid (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University of Sao Paulo General Hospital

Official(s) and/or principal investigator(s):
Elias David-Neto, MD, Principal Investigator, Affiliation: University of Sao Paulo

Summary

The purpose of this study is to determine whether zolendronic acid, a third generation bisphosphonate, is effective in preventing bone loss in the first year after kidney transplantation.

Clinical Details

Official title: A Prospective and Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year After Kidney Transplantation

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Differences in bone turnover

Secondary outcome:

Bone microarchitecture

Changes in Bone Mineral Density

Detailed description: For the treatment of osteoporosis in the general population, a number of drugs reduce BMD (bone mineral density) loss and the rate of incident fractures. For instance, bisphosphonates improve BMD, reduce hip fracture rates and decrease mortality in post-menopausal women. Because of lack of data on safety and an increased risk of adverse effects, the use of these drugs is controversial in patients with chronic kidney disease (CKD) and abnormalities of PTH or vitamin D, an estimated glomerular filtration rate (GFR) less than 30 ml/min/1. 73m² (CKD stages 4 and 5) and after transplantation. The efficacy of short and long term bisphosphonate treatment after kidney transplantation has been examined; however, histomorphometric and fracture rate reduction data are lacking. The purpose of this study is to determine whether zolendronic acid, a third generation bisphosphonate, is effective in preventing bone loss in the first year after kidney transplantation.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- All adult kidney transplant recipients who were stable perioperative and able to

return for regular follow-up Exclusion Criteria:

- Glomerular filtration rate < 30 ml/min/1. 73m² one week after transplantation

- Previous parathyroidectomy or diagnosis of adynamic bone disease (with bone biopsy)

Locations and Contacts

Hospital das Clinicas - Faculdade de Medicina da Universidade de São Paulo, Sao Paulo 05403-900, Brazil
Additional Information

Starting date: July 2012
Last updated: May 16, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017